An improved end-of-life performance for suspension pMDIs with Presspart plasma treated canisters
Ameet Sule, Abhay Singh, Dan Heyworth, Richard Turner, Andrew Newman
H&T Presspart Inhalation Product Technology Centre, Whitebirk Industrial Estate, Blackburn BB1 5RF, UK
Drug deposition on the inner walls of the pMDI canister is a reported phenomenon, occurring by adhesion [[i]] or adsorption [[ii]]. The loss of drug to the walls of the canister will result in variability in the delivered dose from the pMDI through life. Interactions between canister and formulation can also catalyse chemical degradation of the drug . Presspart’s patented fluorocarbon polymerised (FCP) plasma treatment offers a solution to overcome the challenges of drug deposition and interaction with the aluminium alloy canister.
A study was conducted to evaluate the performance of FCP plasma-treated and untreated aluminium alloy canisters, when used in conjunction with a budesonide HFA suspension formulation. Performance was evaluated by assessment of delivered dose through life, tail-off characteristics and drug deposition on canister walls.